United Therapeutics Corporation (UTHR) FY2026 Q2 Balance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
United Therapeutics Corporation (UTHR) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$607.80 MLiabilities$819.80 MNon-current liabilities$212.00 MCurrent assets$3.48 BEquity$6.40 BGross equity(calculated)$12.06 BAssets$7.22 BNon-current assets$3.74 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsMarketable investmentsOther current assetsAccounts receivable, no allowance for 2026 and 2025Inventories, netProperty, plant, and equipment, netMarketable investmentsDeferred tax assets, netOther non-current assetsGoodwill and other intangible assets, netAccounts payable and accrued expensesOther current liabilitiesOther non-current liabilitiesRetained earningsAdditional paid-in capitalCommon stock, par value $0.01, 245,000,000 shares authorized, 78,029,318 and 76,452,253 shares issued, and 42,676,835 and 43,643,165 shares outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury stock, 35,352,483 and 32,809,088 shares as of June 30, 2026 and December 31, 2025, respectivelyAccumulated other comprehensive (loss) incomeCurrent liabilitiesCurrent liabilities$607.80 MAccounts payable and accrued expensesAccounts payable and accrued expenses$497.80 MLiabilitiesLiabilities$819.80 MOther current liabilitiesOther current liabilities$110.00 MNon-current liabilitiesNon-current liabilities$212.00 MCurrent assetsCurrent assets$3.48 BOther non-current liabilitiesOther non-current liabilities$212.00 MCash and cash equivalentsCash and cash equivalents$1.80 BEquityEquity$6.40 BGross equity (calculated)Gross equity(calculated)$12.06 BAssetsAssets$7.22 BMarketable investmentsMarketable investments$859.10 MOther current assetsOther current assets$317.30 MAccounts receivable, no allowance for 2026 and 2025Accounts receivable, no allowance for 2026 and 2025$310.30 MInventories, netInventories, net$193.80 MNon-current assetsNon-current assets$3.74 BRetained earningsRetained earnings$9.16 BProperty, plant, and equipment, netProperty, plant, and equipment, net$1.93 BMarketable investmentsMarketable investments$1.14 BDeferred tax assets, netDeferred tax assets, net$311.60 MOther non-current assetsOther non-current assets$239.50 MGoodwill and other intangible assets, netGoodwill and other intangible assets, net$114.10 MAdditional paid-in capitalAdditional paid-in capital$2.90 BCommon stock, par value $0.01, 245,000,000 shares authorized, 78,029,318 and 76,452,253 shares issued, and 42,676,835 and 43,643,165 shares outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$800.00 KTreasury stock, 35,352,483 and 32,809,088 shares as of June 30, 2026 and December 31, 2025, respectivelyTreasury stock−$5.64 BAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$16.20 M
Chart details

United Therapeutics Corporation (UTHR) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
7,220,100,000 US dollars
Current assets
3,483,700,000 US dollars
Non-current assets
3,736,400,000 US dollars
Liabilities
819,800,000 US dollars
Current liabilities
607,800,000 US dollars
Non-current liabilities
212,000,000 US dollars
Equity
6,400,300,000 US dollars
Cash and cash equivalents
1,803,200,000 US dollars
Marketable investments
859,100,000 US dollars
Other current assets
317,300,000 US dollars
Accounts receivable, no allowance for 2026 and 2025
310,300,000 US dollars
Inventories, net
193,800,000 US dollars
Property, plant, and equipment, net
1,930,100,000 US dollars
Marketable investments
1,141,100,000 US dollars
Deferred tax assets, net
311,600,000 US dollars
Other non-current assets
239,500,000 US dollars
Goodwill and other intangible assets, net
114,100,000 US dollars
Accounts payable and accrued expenses
497,800,000 US dollars
Other current liabilities
110,000,000 US dollars
Other non-current liabilities
212,000,000 US dollars
Retained earnings
9,164,800,000 US dollars
Additional paid-in capital
2,895,800,000 US dollars
Common stock, par value $0.01, 245,000,000 shares authorized, 78,029,318 and 76,452,253 shares issued, and 42,676,835 and 43,643,165 shares outstanding as of June 30, 2026 and December 31, 2025, respectively
800,000 US dollars
Preferred stock, par value $0.01, 10,000,000 shares authorized, no shares issued
0 US dollars
Treasury stock, 35,352,483 and 32,809,088 shares as of June 30, 2026 and December 31, 2025, respectively
negative 5,644,900,000 US dollars
Accumulated other comprehensive (loss) income
negative 16,200,000 US dollars
Gross equity (calculated)
12,061,400,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
United Therapeutics Corporation (UTHR) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!